本文選題：胃癌　切入點：惡性腹腔積液　出處：《中醫(yī)雜志》2017年11期 　論文類型：期刊論文

【摘要】：目的探討消脹抑瘤方聯(lián)合全身及腹腔內(nèi)化療治療晚期胃癌所致惡性腹腔積液的臨床療效及安全性。方法 70例晚期胃癌所致惡性腹腔積液辨證屬肝郁脾虛證型患者,按隨機數(shù)表法分成治療組和對照組各35例。對照組僅給予左亞葉酸鈣100 mg/m~2+5-氟尿嘧啶2.0 g/m~2+紫杉醇95 mg/m2(靜脈滴注)+紫杉醇30 mg/m~2(腹腔灌注化療)雙周方案化療。治療組采用相同方案化療,并口服消脹抑瘤方,每日1劑。兩組療程均為30天,療程結束后觀察兩組患者腹腔積液療效及中醫(yī)證候療效,治療期間記錄引流腹腔積液次數(shù)、化療毒副反應發(fā)生情況。結果治療組腹腔積液療效有效率為62.86%,穩(wěn)定率為85.71%;對照組分別為為51.43%和62.86%,治療組穩(wěn)定率優(yōu)于對照組(P0.05)。治療組引流腹水次數(shù)顯著少于對照組(P0.05)。治療組惡心、嘔吐,腹瀉,中性粒細胞下降,轉氨酶升高等化療毒副反應的發(fā)生率顯著低于對照組(P0.05)。治療組中醫(yī)證候療效優(yōu)于對照組(P0.05)。結論消脹抑瘤方聯(lián)合全身及腹腔內(nèi)化療治療肝郁脾虛型胃癌所致惡性腹腔積液患者,與單純化療相比,可提高腹腔積液治療穩(wěn)定率,減少治療過程中引流腹水次數(shù),減輕化療毒副反應,改善中醫(yī)證候,且臨床應用安全。
[Abstract]:Objective to investigate the clinical efficacy and safety of Xiaodong Yi tumor recipe combined with systemic and intraperitoneal chemotherapy in the treatment of malignant peritoneal effusion caused by advanced gastric cancer. Methods 70 patients with malignant peritoneal effusion caused by advanced gastric cancer were diagnosed as liver stagnation and spleen deficiency syndrome. According to the random list method, the treatment group and the control group were divided into treatment group (n = 35) and control group (n = 35). The control group was treated with only levoflavone 100 mg/m~2 5-fluorouracil 2.0 g / m ~ 2 paclitaxel 95 mg / m ~ (2) paclitaxel 30 mg / m ~ (2) paclitaxel 30 mg 路m ~ (2) (intraperitoneal infusion chemotherapy) biweekly chemotherapy. The group received the same regimen of chemotherapy, The treatment course of both groups was 30 days. After the treatment, the curative effect of celiac effusion and TCM syndrome were observed, and the times of drainage of peritoneal effusion were recorded during the treatment. Results the effective rate of peritoneal effusion in the treatment group was 62.86, the stability rate was 85.71, in the control group it was 51.43% and 62.86, respectively. The stable rate in the treatment group was better than that in the control group (P 0.05). The number of drainage ascites in the treatment group was significantly less than that in the control group. Vomiting, diarrhea, neutropenia, The incidence of side effects of chemotherapy such as elevation of aminotransferase was significantly lower than that of control group P0.05.The curative effect of TCM syndrome in the treatment group was better than that in the control group. Conclusion the treatment of malignant peritoneal effusion caused by liver stagnation and spleen deficiency gastric cancer by the combination of Xiaotong Yi tumor recipe and intraperitoneal chemotherapy is better than that of the control group. Compared with chemotherapy alone, it can improve the stable rate of peritoneal effusion, reduce the times of drainage ascites, alleviate the side effects of chemotherapy, improve the syndrome of traditional Chinese medicine, and the clinical application is safe.
【作者單位】： 福建省腫瘤醫(yī)院;福建省中醫(yī)藥研究院;
【基金】：福建省自然科學基金(2015J01437) 福建省衛(wèi)生計生委國家臨床重點�？平ㄔO項目(2013年度)
【分類號】：R273

【相似文獻】

相關期刊論文 前7條

1 張宗岐;惡性腹腔積液的中醫(yī)治療特色[J];家庭中醫(yī)藥;2002年11期

2 崔虎軍;;木香順氣丸治療惡性腹腔積液腹脹的臨床研究[J];中醫(yī)學報;2012年08期

3 董明娥;李健;;內(nèi)金術茅湯治療惡性腹腔積液56例[J];陜西中醫(yī);2007年04期

4 奚穎;周微紅;;周維順教授治療腫瘤晚期惡性腹腔積液經(jīng)驗[J];長春中醫(yī)藥大學學報;2012年05期

5 何玉梅;薛素芬;許麗萍;李佩文;;外敷中藥消水Ⅱ號治療惡性腹腔積液免疫學探討[J];醫(yī)學研究雜志;2006年09期

6 杜祖光;張濤;李海英;趙振愛;折哲;;中藥逐水復方神闕穴外敷對惡性腹腔積液患者免疫功能的影響[J];山西醫(yī)藥雜志;2012年02期

7 ;[J];;年期

相關碩士學位論文 前1條

1 高辰;中醫(yī)外治惡性腹腔積液的臨床研究[D];北京中醫(yī)藥大學;2013年

，

本文編號：1627723